Examples of using Podhaler in English and their translations into Swedish
{-}
-
Colloquial
-
Official
-
Medicine
-
Ecclesiastic
-
Ecclesiastic
-
Official/political
-
Computer
-
Programming
-
Political
Do not take TOBI Podhaler.
What TOBI Podhaler is used for.
When to take TOBI Podhaler.
How TOBI Podhaler works.
How long to take TOBI Podhaler.
People also translate
Why has Tobi Podhaler been approved?
Other medicines and TOBI Podhaler.
What is Tobi Podhaler used for?
If you forget to take TOBI Podhaler.
How much TOBI Podhaler to take.
TOBI Podhaler capsules must not be swallowed.
Inside your TOBI Podhaler weekly pack.
What you need to know before you take TOBI Podhaler.
How has Tobi Podhaler been studied?
No interaction studies have been performed with TOBI Podhaler.
What TOBI Podhaler is and what it is used for.
Each weekly carton of TOBI Podhaler contains.
TOBI Podhaler 28 mg inhalation powder, hard capsules.
What benefit has Tobi Podhaler shown during the studies?
Tobi Podhaler is inhaled using a hand-held device called Podhaler.
Nephrotoxicity was not observed during TOBI Podhaler clinical studies.
TOBI Podhaler is administered by inhalation using the Podhaler device see section 6.6 for detailed instructions for use.
Caution should be exercised when prescribing TOBI Podhaler to patients with known or suspected renal dysfunction.
Tobi Podhaler was studied in two main trials in patients who had cystic fibrosis with P. aeruginosa lung infection.
The European Commission granted a marketing authorisation valid throughout the European Union for Tobi Podhaler on 20 July 2011.
Caution should be exercised when prescribing TOBI Podhaler to patients with known
audiological assessment before initiating TOBI Podhaler therapy.
hearing loss during TOBI Podhaler therapy the physician should consider referring them for audiological assessment.
Systemic exposure following inhalation of TOBI Podhaler is very low, however TOBI Podhaler should not be used during pregnancy unless clearly necessary,
If oto- or nephrotoxicity occurs in a patient receiving TOBI Podhaler, tobramycin therapy should be discontinued until serum concentration falls below 2 µg/ml.